北京若生智能科技有限公司
Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Mylan研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Abevmy, bevacizumab, Biocon, Krabeva
公司Mylan
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Mylan

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedClinical and translational radiation oncology2026-10-27

Longitudinal tumor response dynamics after staged gamma knife radiosurgery combined with bevacizumab in sporadic vestibular schwannoma.

Peng Zeyu Z, Wang Shangbo S, Cao Jiao-Jiao JJ, Zhang Hongchi H et al.

Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve. Although Gamma Knife radiosurgery (GKRS) achieves durable tumor control, delayed regression and pseudoprogression remain clinical challenges. Staged GKRS combined with bevacizumab may alter post-radiosurgical tumor response patterns. To compare longitudinal tumor response, pseudoprogression, and clinical outcomes between staged GKRS combined with bevacizumab and single-session GKRS alone in sporadic VSs. We retrospectively reviewed 72 patients with sporadic VSs: 49 treated with staged GKRS plus bevacizumab and 23 with single-session GKRS alone. Longitudinal tumor volume changes were analyzed using multivariable linear mixed-effects models, while early volumetric enlargement was evaluated using Kaplan-Meier estimates and Cox proportional hazards models. Compared with GKRS alone, staged GKRS plus bevacizumab showed significantly different response trajectories (treatment-by-time interaction, P < 0.001), with earlier and sustained regression. Greater tumor reduction was observed from 3 to 36 months (all adjusted P < 0.05). Early volumetric enlargement (>10%) occurred in 14.3% versus 60.9% of patients (HR, 0.16; 95% CI, 0.06-0.40; P < 0.001). Pseudoprogression occurred in 4.1% versus 17.4% of patients, without statistical significance (P = 0.078). Cystic tumor composition was independently associated with greater regression. BEV-related adverse events were mild and manageable. Staged GKRS combined with bevacizumab was associated with earlier, more sustained tumor regression and a lower risk of early post-treatment enlargement in sporadic VSs. Larger baseline tumor volume and cystic composition were associated with greater regression. Pseudoprogression was numerically less frequent, although the difference was not statistically significant. ChiCTR2600131856 (Chinese Clinical Trial Registry).

PMID 42936495
阅读全文 →
PubMedFrontiers in immunology2026-10-27

Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC: the SPIRAL-STONE study.

Ishida Masaki M, Yamada Tadaaki T, Kamada Riko R, Hibino Makoto M et al.

Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung cancer is associated with a poor prognosis, underscoring the need for effective pharmacological treatments. An exploratory subgroup analysis of IMpower150 suggested potential clinical benefit of the atezolizumab-containing regimen in KRAS-mutant non-squamous NSCLC, although prospective data remain limited. We prospectively evaluated its efficacy and safety and performed exploratory biomarker analyses. The study cohort comprised patients with advanced or recurrent KRAS-mutant non-squamous NSCLC scheduled to receive ICI plus bevacizumab-based chemotherapy at 10 Japanese institutions between January 2023 and December 2024. The primary endpoint was progression-free survival (PFS). Secondary endpoints included disease control rate (DCR), objective response rate (ORR), overall survival (OS), and safety. Associations between baseline serum levels of vascular endothelial growth factor (VEGF)-A and VEGF-D and treatment outcomes were explored in patients with available pretreatment samples. Of 22 enrolled patients, 21 received treatment and were analyzed for efficacy and safety; 17 were analyzed for serum biomarkers. All patients received atezolizumab, bevacizumab, carboplatin, and paclitaxel. The median PFS and OS were 6.0 and 17.1 months, respectively. Among 19 patients with measurable disease, the ORR was 42.1%, and the DCR was 68.4%. Grade ≥3 hematologic and non-hematologic adverse events occurred in 33.3% and 47.6% of patients, respectively. Baseline serum VEGF-A and VEGF-D levels were not significantly associated with the treatment outcomes. ICI plus bevacizumab-based chemotherapy showed an ORR of 42.1%, a median PFS of 6.0 months, and a median OS of 17.1 months in patients with KRAS-mutant non-squamous NSCLC. Given the small sample size and single-arm design, these findings should be considered descriptive and hypothesis-generating. Pretreatment serum VEGF-A and VEGF-D levels were not significantly associated with clinical outcomes, although limited statistical power precludes definitive conclusions. Larger comparative studies with comprehensive molecular profiling are warranted.

PMID 42935986
阅读全文 →
PubMedCancers2026-10-27

Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score.

Iino Chikara C, Abe Tamami T, Endo Kei K, Fujiwara Yudai Y et al.

Background/Objectives: Sustained drug-free status is an emerging milestone after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. We examined baseline host biomarkers associated with achievement of 6-month sustained drug-free status and evaluated a composite stratification score. Methods: This multicentre retrospective study included patients treated with atezolizumab plus bevacizumab. The endpoint required systemic therapy discontinuation after complete response or no viable disease, followed by at least 6 months without viable or recurrent hepatocellular carcinoma and sustained normalization of initially elevated tumour markers. The PAN-DF score (preserved hepatic reserve, altered immune-inflammatory status, and nutritional-immune reserve for achieving drug-free status) combined modified albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, and prognostic nutritional index. Results: Among 655 patients, 25 achieved the endpoint; median post-discontinuation follow-up was 533 days. In the complete-case cohort (n = 473; 17 events), achievement rates were 0.0%, 2.9%, 3.7%, and 13.6% for scores 0-3. Each one-point increase was associated with higher odds of achievement (odds ratio 2.90, 95% confidence interval 1.51-5.55; p = 0.001), and the area under the curve was 0.719. The examined baseline tumour-related factors were not significantly associated with the primary endpoint, and the examined host-related factors were not associated with objective response. Conclusions: Selected baseline host biomarkers were associated with achievement of 6-month sustained drug-free status. PAN-DF stratified the observed probability of this outcome and may help identify patient groups with a relatively higher likelihood of a sustained drug-free state, supporting early multidisciplinary planning.

PMID 42938898
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study.

Deng Zekun Z, Cai Hongqing H, Chen Yujia Y, Liu Qi Q et al.

Background: Salvage options for recurrent grade 4 glioma (GBM) remain limited and no single standard of care has been established after recurrence. Teniposide (VM-26) has been reintroduced into clinical practice, but its benefit when added to temozolomide (TMZ) plus bevacizumab (Bev) in recurrent grade 4 glioma remains unclear. Methods: This single-center, real-world exploratory study retrospectively enrolled 53 patients with recurrent grade 4 glioma who received either teniposide plus TMZ and Bev (VM26 + TMZ + Bev, n = 26) or TMZ plus Bev (TMZ + Bev, n = 27). The control group combined patients treated before teniposide became available again in China (2020-2022) with those treated concurrently with the triplet (2023-2026). Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0; tumor response was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria on an intention-to-treat basis, and survival was estimated by the Kaplan-Meier method. Results: Median progression-free survival (PFS) was 7.8 months (95% confidence interval (CI), 4.9-10.9) in the VM26 + TMZ + Bev group versus 5.1 months (95% CI, 4.4-6.8) in the TMZ + Bev group (log-rank p = 0.037; unadjusted hazard ratio (HR) 0.50, 95% CI, 0.25-0.97), and median overall survival (OS) was 12.7 months (95% CI, 8.4-15.4) versus 8.5 months (95% CI, 7.3-9.7) (log-rank p = 0.042; unadjusted HR 0.47, 95% CI, 0.23-0.98). Multivariable adjustment strengthened these estimates, whereas propensity score weighting and matching gave estimates of the same direction that did not reach significance. The objective response rate (ORR) was 26.9% (7/26) versus 14.8% (4/27) (p = 0.327) and the disease control rate (DCR) was 80.8% versus 77.8% (p = 1.000). Grade ≥ 3 adverse events (AEs) occurred in 11.5% versus 7.4% of patients (p = 0.669); leukopenia and neutropenia were more frequent with teniposide (26.9% vs. 3.7%; p = 0.024) but lost significance after Benjamini-Hochberg correction (q = 0.122). No unexpected toxicity types were observed, although any-grade leukopenia and neutropenia were more frequent with teniposide and should be anticipated in clinical use. Conclusions: In this exploratory real-world cohort, adding teniposide to TMZ plus Bev was associated with longer PFS and OS and a numerically higher ORR, without a significant increase in grade ≥ 3 toxicity, although any-grade leukopenia and neutropenia were more frequent and should be anticipated; however, treatment era could not be fully separated from treatment effect: in an era-matched analysis restricted to the concurrently treated cohorts, the direction of the effect was preserved but did not reach significance. The survival differences rested on a small number of events and were not robust to reclassification of individual patient outcomes. These findings warrant confirmation in prospective randomized studies.

PMID 42941343
阅读全文 →
PubMedCurrent issues in molecular biology2026-10-27

Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13-CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma.

Uccello Mario M

Transcriptomic response biomarkers for immune-checkpoint blockade remain poorly defined across cancers. We developed the two-gene Myeloid-Adaptive Response to Atezolizumab (MARTA) score, integrating CXCL13 and CXCL8 expression. MARTA was developed in 81 atezolizumab-treated patients in IMmotion150, evaluated across treatment groups, and independently assessed in IMvigor210. In IMmotion150, higher MARTA was associated with higher objective response rate (ORR) with atezolizumab alone (odds ratio [OR], 3.20; 95% confidence interval [CI], 1.42-7.19) and atezolizumab plus bevacizumab (OR, 2.61; 95% CI, 1.43-4.76), but not with sunitinib. Higher MARTA was associated with longer progression-free survival (PFS) in both atezolizumab-containing groups (hazard ratio [HR], 0.60 and 0.65), but not with sunitinib (interaction p = 0.01). In IMvigor210, higher MARTA was associated with higher ORR (OR per 1-standard-deviation increase, 1.38; 95% CI, 1.05-1.81) and longer overall survival (OS) (HR, 0.76; 95% CI, 0.67-0.86). The OS association remained after multivariate adjustment (HR, 0.81; 95% CI, 0.69-0.95). Discrimination for ORR and OS, assessed by the area under the curve (AUC) and C-index, respectively, was modest for MARTA, tGE8, and the IFN-γ signature. These findings support further evaluation of MARTA, while prospective validation and cross-platform analytical reproducibility remain necessary before clinical application.

PMID 42939550
阅读全文 →
PubMedPharmaceutics2026-10-27

Airway Transepithelial Transport of IgG Formulated with Excipients: A Case Study on What to Consider Regarding Impact on Epithelial Barrier Integrity, IgG Quality and Matrix Effects During the Analytics.

Rittersberger Rebecca R, Koslowski Gabriel G, Shrimo Iman I, Schindowski Katharina K

Background: Surface-active excipients such as polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (Px188), and cyclodextrin (CD) are widely used to stabilize IgG formulations, including aerosols. However, their effects on transepithelial IgG transport and the reliability of associated analytical readouts remain poorly understood. Methods: Transepithelial transport of Bevacizumab was quantified across a primary airway epithelial model in the presence of clinically relevant concentrations of PS20, PS80, Px188, or CD using ELISA. Potential methodological bias was assessed by cytotoxicity and barrier integrity (Alamar Blue, LDH, TEER), IgG monomer content (SE-HPLC), micelle formation and excipient passage, and ELISA matrix effects using excipient-containing calibration curves. Results: Only CD at 10 mg/mL significantly increased IgG transport, whereas PS20, PS80, and Px188 had no significant effect. All excipients were non-toxic, with TEER being the most sensitive indicator. IgG monomer content remained unchanged under all conditions. Micelle-forming activity of PS20, PS80, and CD was retained, but only CD (10 mg/mL) crossed the epithelial barrier (11% of the initial concentration). Excipients caused concentration-dependent ELISA matrix effects; however, matrix-adjusted quantification showed only a modest, non-significant change in calculated IgG transport for CD. Conclusions: Excipients can influence in vitro IgG transport studies through biological and analytical mechanisms. Under the tested conditions, the increased IgG transport observed with CD appears to be genuine rather than assay-related, highlighting the importance of controlling excipient-related effects in mucosal IgG transport studies.

PMID 42942794
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab